Evidence Trace, complete trial record
In plain terms
In plain terms: Exosome Therapy (extracellular vesicles) shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.
Exosome Therapy (extracellular vesicles)
C
Limited: small, mixed or unreplicated trials
The endpoint this grade is based on: Surrogate biomarker endpoint
The evidence as the record states it
Skin: Park et al. (J Cosmet Dermatol, 2023; PMID 37377400): randomized split-face trial, 28 subjects, an adipose stem cell exosome solution with microneedling against saline with microneedling, three sessions over 12 weeks; wrinkles, elasticity, hydration and pigmentation measured by instrument; funded by the National Research Foundation of Korea. Choi et al. (J Microbiol, 2026; PMID 42403177): split-face randomized trial, 16 adults, the same adipose stem cell exosome product delivered by ultrasound against saline; water loss fell and hydration and elasticity rose; the product's maker, ExoCoBio, supplied it and funded the study, and the authors overlap with Park 2023, so this is the same group, not independent replication. Yen et al. (J Craniofac Surg, 2026; PMID 42635327): unblinded split-face randomized trial, 60 adults, a topical extracellular vesicle preparation after radiofrequency microneedling against microneedling alone; wrinkle score improved 3.3 points more at 12 weeks; no conflicts reported. Park and Park (Life, 2026; PMID 41752855): 75 patients with postoperative facial scars randomized to laser alone or laser with human-derived or plant-derived exosome boosters; numerically greater short-term scar and skin-quality improvement, human and plant products comparable; hospital-funded. Huang et al. (Aesthet Surg J, 2026; PMID 41800727): six-subject preliminary split-face study of rose stem cell exosomes after needling radiofrequency. Stack et al. (Aesthet Surg J, 2026; PMID 41800726): pooled 39 mostly uncontrolled studies, 20.2 percent wrinkle reduction, and rated its own work Level of Evidence 3; it contains no knee or systemic trial and supports nothing beyond the fact that studies exist. Knee: Bolandnazar et al. (BMC Musculoskelet Disord, 2024; PMID 39465400): triple-blind placebo-controlled trial, 31 patients, each with one knee injected with placental stromal cell extracellular vesicles and the other with saline; no difference in pain, function or MRI at 2 and 6 months. Hair: Amini et al. (Life, 2025; PMID 40141845): randomized saline-controlled pilot, 20 men, a plant-derived exosome formulation, more hair growth; not indexed under the randomized trial publication type. Grade C on skin: small split-face trials with instrument-measured surrogate endpoints, mostly unblinded, of different products.
PMID 37377400 PMID 42403177 PMID 42635327 PMID 41752855 PMID 41800727 PMID 41800726 PMID 39465400 PMID 40141845
Evidence by specific use
Facial skin quality (topical, after microneedling or RF)
Grade C
Park et al. (J Cosmet Dermatol, 2023; PMID 37377400) randomized 28 subjects in a split-face design, three sessions over 12 weeks, and measured with PRIMOS, Cutometer and Corneometer rather than by eye. Choi et al. (J Microbiol, 2026; PMID 42403177) repeated the design in 16 adults with the same product, funded and supplied by its maker, ExoCoBio, from the same group; not independent replication. Yen et al. (J Craniofac Surg, 2026; PMID 42635327), 60 adults, unblinded, a different topical preparation after radiofrequency microneedling, wrinkle score 3.3 points better than microneedling alone at 12 weeks. Park and Park (Life, 2026; PMID 41752855), 75 patients, exosome boosters with laser for scars and skin quality, numerically better. Huang et al. (Aesthet Surg J, 2026; PMID 41800727) is n=6 and calls itself preliminary. Stack et al. (PMID 41800726) pooled 39 mostly uncontrolled studies and graded its own work Level of Evidence 3. C: several small split-face trials of different products, mostly unblinded, with instrument-measured surrogate endpoints, which cap this at B regardless of how many more appear.
PMID 37377400 PMID 42403177 PMID 42635327 PMID 41752855 PMID 41800727 PMID 41800726
Hair growth in androgenetic alopecia, plant-derived exosome formulation (scalp injection)
Grade C
Amini et al. (Life (Basel), 2025; PMID 40141845): randomized saline-controlled trial, 20 men with Norwood 2 to 3 androgenetic alopecia, an exosome formulation containing Ecklonia cava and Thuja orientalis extracts or saline, four scalp sessions over eight weeks, hair count at week 16; hair count rose in the treated group and not on saline (between-group p = 0.006, large effect), no adverse events, authors declare no conflicts. One small positive randomized trial, unreplicated: C. This row grades the plant-derived formulation tested; it says nothing about the human stem-cell-derived exosome products sold for hair, which have their own row below.
PMID 40141845
Hair growth, human stem-cell-derived exosomes (the products sold)
Grade D
No randomized trial of human stem-cell-derived exosomes for hair growth has been found. The one randomized hair trial (Amini 2025, PMID 40141845) tested a plant-extract formulation and is graded on its own row. The 13 hair studies pooled by Stack 2026 are uncontrolled. Route 1: the product class that clinics sell for hair has not been tested in a randomized trial.
Orthopedic / knee osteoarthritis / cartilage
Grade D
Tested and no benefit. Bolandnazar et al. (BMC Musculoskelet Disord, 2024; PMID 39465400) was a triple-blind placebo-controlled trial in 31 patients with bilateral knee osteoarthritis, one knee injected with placental stromal cell-derived extracellular vesicles and the other with saline; no difference in pain, WOMAC, Lequesne or MRI at 2 and 6 months. This is among the most heavily marketed indications.
PMID 39465400
Systemic or intravenous administration for longevity, healthspan or anti-aging
Grade D
No randomized trial exists for the use that is actually sold. Intravenous exosome infusion is offered commercially for aging, energy and recovery. Nothing randomized supports any of it. This is the gap between what the biology suggests and what has been tested, and it is the whole reason this entry exists.
Why Grade C and not Grade B
Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.
What this grade covers and what it does not
Grade C on instrument-measured facial skin quality, from small randomized split-face trials: 28 subjects, an adipose stem cell exosome solution with microneedling against saline (Park et al., 2023; PMID 37377400), repeated in 16 adults with the same product and the maker's funding (Choi et al., 2026; PMID 42403177). Other uses carry their own letters: knee osteoarthritis is D, tested and null (PMID 39465400); hair growth is C for one small, unreplicated trial of a plant-derived formulation (PMID 40141845) and D for the human stem-cell-derived products sold for hair, which have no randomized trial. WHAT THIS GRADE DOES NOT COVER: intravenous or systemic infusion for aging, the use that is sold, for which no randomized trial exists. There are no FDA-approved exosome products.
What would move this grade
A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.
How to track whether this is working
This intervention remains investigational with no standardized clinical protocol. If enrolled in a formal protocol, track the primary endpoint defined by that protocol at the specified intervals. Source, dosing, and route of administration are consistent with any published protocol used as a reference.